EPALINGES, Switzerland, Oct. 27, 2025 /PRNewswire/ -- Onward Therapeutics SA, a clinical stage oncology company, today announced that its French subsidiary, Onward Therapeutics France, has exercised its exclusive option and entered into a worldwide license agreement with Institut du Cancer de Montpellier (ICM), France, to further advance a breakthrough program in onco-metabolism.
kAm%9:D =:46?D6 28C66>6?E 3F:=5D FA@? E96 6I4=FD:G6 4@==23@C2E:@? 2?5 @AE:@? 28C66>6?E D:8?65 36EH66? ~?H2C5 %96C2A6FE:4D uC2?46 2?5 xr|[ x?D6C> 2?5 &?:G6CD:Eé 56 |@?EA6==:6C :? yF?6 a_a`[ F?56C H9:49 E96 4@>A2?J AC@G:565 C6D62C49 7F?5:?8 E@ DFAA@CE E96 5:D4@G6CJ AC@8C2> 2E xr|] %96 DF446DD7F= AC@8C6DD 249:6G65 E9C@F89 E9:D 4@==23@C2E:@? 92D =65 E@ E96 :56?E:7:42E:@? @7  AC@>:D:?8 4@>A@F?5D  2?5 E96 EC2?D:E:@? @7 E96 5CF8 5:D4@G6CJ AC@8C2> :?E@ ~?H2C5 %96C2A6FE:4DV 56G6=@A>6?E A:A6=:?6] %96 AC@8C2> :D 4FCC6?E=J :? =625 @AE:>:K2E:@?[ H:E9 E96 8@2= @7 ?@>:?2E:?8 x}s\6?23=:?8 42?5:52E6D ?6IE J62C]k^Am
kAm%96 AC@8C2>[ 56D:8?2E65 ~%\$__) 3J ~?H2C5 %96C2A6FE:4D[ :D 2? :??@G2E:G6Â @?4@\>6E23@=:D> AC@;64E 2:>65 2E 6IA2?5:?8 E96C2A6FE:4 A@DD:3:=:E:6D :? 42?46C EC62E>6?E] !C@@7\@7\AC:?4:A=6 DEF5:6D 92G6 56>@?DEC2E65 DEC@?8 AC64=:?:42= 677:424J[ 2?5 AC@>:D:?8 42?5:52E6D 7C@> EH@ 5:DE:?4E 496>:42= D6C:6D Â 92G6 2=C625J 366? :56?E:7:65[ 2?5 4@>A@F?5D H:E9 :>AC@G65 A9JD:4@\496>:42= AC@A6CE:6D H:== 36 86?6C2E65 E9C@F89 2CE:7:4:2= :?E6==:86?46 2AAC@2496D]k^Am
kAmQ~%\$__) C6AC6D6?ED 2 3C62<E9C@F89 :? E2C86E:?8 EF>@C @?4@\>6E23@=:D>] !C64=:?:42= DEF5:6D 92G6 D9@H? E92E E96 677:424J @7  E96D6 4@>A@F?5D DEC@?8=J 4@CC6=2E6D H:E9  2 AC65:4E:G6 3:@>2C<6C @7 C6DA@?D6 24C@DD >F=E:A=6 EF>@C EJA6D[ AC@G:5:?8 2 4=62C C2E:@?2=6 7@C E9:D ?@G6= >6492?:D> @7 24E:@?]kDA2? :5lQDA2?w89=Ed2baQmQk^DA2?m D2:5 sC] pC>2?5 56 vC2>@?E[ r9:67 $4:6?E:7:4 ~77:46C @7 ~?H2C5 %96C2A6FE:4D]Q~%\$__) :?EC@5F46D 2 5:776C6?E:2E65 >6E23@=:4 DEC2E68J E92E 3C@256?D @FC A:A6=:?6 2?5 AC:>2C:=J AC@G:56D 2? :??@G2E:G6 H2J E@ E24<=6 42?46C C6D:DE2?46kDA2? :5lQDA2?w89=EbbahQm[k^DA2?mQ 25565 sC p=2:? w6CC6C2[ !C6D:56?E @7 ~?H2C5 %96C2A6FE:4D uC2?46 2?5 r9:67 |65:42= ~77:46C @7 ~?H2C5 %96C2A6FE:4D]k^Am
kAmQ(6 2C6 56=:89E65 E@ DEC6?8E96? @FC 4@==23@C2E:@? H:E9 ~?H2C5 %96C2A6FE:4D[Q D2:5 !C@7] |2C4 *49@F[ s:C64E6FC vé?éC2= @7 xr|] Q%96 :??@G2E:G6 ~%\$__) AC@8C2>[ :?:E:2==J 56G6=@A65 3J @FC C6D62C49 E62>D E@86E96C H:E9 x?D6C> 2?5 &?:G6CD:Eé 56 |@?EA6==:6C[ 56>@?DEC2E6D E96 A@E6?E:2= @7 EC2?D=2E:@?2= D4:6?46 E@ 86?6C2E6 ?@G6= E96C2A6FE:4 DEC2E68:6D :? @?4@=@8J] xE 2=D@ 9:89=:89ED E96 :?E6C?2E:@?2= C6249 @7 xr| 2?5 E96 DEC6?8E9 @7 E96 |@?EA6==:6C |65'2==é6 64@DJDE6> :? 5C:G:?8 42?46C :??@G2E:@?]Qk^Am
kAmkDEC@?8mp3@FE ~?H2C5 %96C2A6FE:4DÂ k^DEC@?8mk^Am
kAm~?H2C5 %96C2A6FE:4D Wk2 9C67lQ9EEAi^^HHH]@?H2C5\E96C2A6FE:4D]4@>^Q E2C86ElQ03=2?<Q C6=lQ?@7@==@HQmHHH]@?H2C5\E96C2A6FE:4D]4@>k^2mX :D 2 4=:?:42=\DE286 3:@E649?@=@8J 4@>A2?J 7@4FD65 @? 56G6=@A:?8 :??@G2E:G6 42?46C E96C2A:6D] {65 3J 2 D62D@?65 E62> :? EC2?D=2E:@?2= D4:6?46 2?5 5CF8 56G6=@A>6?E[ E96 4@>A2?J 25G2?46D AC@>:D:?8 42?5:52E6D E9C@F89 2 72DE\EC24< 56G6=@A>6?E >@56=] xED A@CE7@=:@ :?4=F56D 2 3:DA64:7:4 2?E:3@5J W~%\pa_`X =:46?D65 7C@> q:@>F?6I !92C>246FE:42=D[ 2=@?8D:56 2? 6BF:EJ :?G6DE>6?Ej 2?5 2? 2==@86?6:4 }z 46== E96C2AJ W~%\r__`X 56G6=@A65 G:2 :ED >2;@C:EJ\@H?65 DF3D:5:2CJ[ t>6C46==] q6J@?5 E96D6 =625 4=:?:42= 2DD6ED[ E96 4@>A2?J :D 56G6=@A:?8 EH@ 7:CDE\:?\4=2DD 62C=J 56G6=@A>6?E AC@8C2>D[ :?4=F5:?8 2 D>2== >@=64F=6 :? @?4@\>6E23@=:D> W~%\$__)X 2?5 2 >F=E:\DA64:7:4 2?E:3@5J A=2E7@C> W~%\pb_)X] %96 4@>A2?J @A6C2E6D :? tA2=:?86D[ !2C:D[ 2?5 %2:A6:]k^Am
kAmkDEC@?8m p3@FE x?DE:EFE 5F r2?46C |@?EA6==:6C Wxr|Xk^DEC@?8mk^Am
kAmu@F?565 :? `hab[ xr| :D @?6 @7 `g uC6?49 r@>AC696?D:G6 r2?46C r6?EC6D 565:42E65 E@ A2E:6?E 42C6[ C6D62C49[ 2?5 :??@G2E:@?] p >6>36C @7 E96 &?:42?46C 8C@FA 2?5 5:C64E65 3J !C@7] |2C4 *49@F[ xr| 4@>3:?6D >F=E:5:D4:A=:?2CJ A2E:6?E >2?286>6?E H:E9 4FEE:?8\6586 C6D62C49 DA2??:?8 7C@> 32D:4 3:@=@8J E@ 4=:?:42= 2AA=:42E:@?D] xED C6D62C49 2C>[ E96 x?DE:EFE 56 #6496C496 6? r2?4éC@=@8:6 56 |@?EA6==:6C Wx#r|X[ 4@\>2?2865 H:E9 x?D6C> 2?5 &?:G6CD:Eé 56 |@?EA6==:6C[ 3C:?8D E@86E96C @G6C a__ C6D62C496CD H@C<:?8 4=@D6=J H:E9 4=:?:4:2?D[ 2?5 :D C64@8?:K65 3J E96 uC6?49 }2E:@?2= r2?46C x?DE:EFE6 2D 2? x?E68C2E65 r2?46C #6D62C49 r6?E6C W$x#xrX]k^Am
kA :5lQ!&#{Qmk:>8 E:E=6lQr:D:@?Q H:5E9lQ`aQ 96:89ElQ`aQ 2=ElQr:D:@?Q DC4lQ9EEADi^^6586]AC?6HDH:C6]4@>^4^:>8^72G:4@?]A?8nD?lwz_ehgaU2>AjD5la_ad\`_\afQ ^m ':6H @C:8:?2= 4@?E6?E E@ 5@H?=@25 >F=E:>65:2ik2 :5lQ!#}&#{Q C6=lQ?@7@==@HQ 9C67lQ9EEADi^^HHH]AC?6HDH:C6]4@>^?6HD\C6=62D6D^@?H2C5\E96C2A6FE:4D\6I6C4:D6D\6I4=FD:G6\@AE:@?\2?5\D:8?D\H@C=5H:56\=:46?D6\28C66>6?E\H:E9\:?DE:EFE\5F\42?46C\56\>@?EA6==:6C\7@C\?@G6=\@?4@\>6E23@=:D>\AC@8C2>\b_adhchbg]9E>=Q E2C86ElQ03=2?<Qm9EEADi^^HHH]AC?6HDH:C6]4@>^?6HD\C6=62D6D^@?H2C5\E96C2A6FE:4D\6I6C4:D6D\6I4=FD:G6\@AE:@?\2?5\D:8?D\H@C=5H:56\=:46?D6\28C66>6?E\H:E9\:?DE:EFE\5F\42?46C\56\>@?EA6==:6C\7@C\?@G6=\@?4@\>6E23@=:D>\AC@8C2>\b_adhchbg]9E>=k^2mk^Am
kAm$~&#rt ~?H2C5 %96C2A6FE:4D $pk^Am
kAmk:>8 2=ElQQ DC4lQ9EEADi^^CE]AC?6HDH:C6]4@>^CE]8:7n}6HDxE6>x5lwz_ehgaU2>Aj%C2?D>:DD:@?0x5la_ad`_afa___!#0}t($0&$!#00000wz_ehgaU2>Ajs2E6x5la_ad`_afQ DEJ=6lQ3@C56Ci_AIj H:5E9i`AIj 96:89Ei`AIjQ ^mk^Am
(0) comments
Welcome to the discussion.
Log In
Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.